Phase I/II Trial of AGS-003

Article

Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.

DURHAM, North Carolina—Argos Therapeutics has begun a phase I/II clinical trial to test the activity and safety of AGS-003, a personalized immunotherapy for advanced kidney cancer. AGS-003 is a second-generation dendritic-cell-based therapy with optimized immune response characteristics designed to stimulate the immune system to target and destroy cancer cells.

Recent Videos
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Related Content
Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Continues to Show Safety and Efficacy in Phase 1/2 Trial

Spur Therapeutics’ Gaucher Disease Gene Therapy FLT201 Continues to Show Safety and Efficacy in Phase 1/2 Trial

Noah Stansfield
February 4th 2025
Article

Among the 5 patients in the efficacy set, 4 patients ceased receiving their previous standard of care therapy.

ImmunoLogic

ImmunoLogic, Episode 1: "Chemo-Free Lymphoma? Seriously?" With Stephen J. Schuster, MD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Noah Stansfield;Matt Hoffman
January 31st 2025
Podcast

In Episode 1 of ImmunoLogic, Stephen J. Schuster, MD, discussed the potential of treating lymphoma without chemotherapy.

United Therapeutics’ Gene-Edited Kidney Xenotranspant UKidney Cleared for US Trial

United Therapeutics’ Gene-Edited Kidney Xenotranspant UKidney Cleared for US Trial

Noah Stansfield
February 3rd 2025
Article

The IND clearance constitutes the first for a xenokidney product.

ImmunoLogic

CGTLive® Presents: ImmunoLogic, A Video Podcast With Joseph Fraietta, PhD

Joseph A. Fraietta, PhD;Noah Stansfield;Matt Hoffman
December 18th 2024
Podcast

Hosted by Joseph Fraietta, PhD, ImmunoLogic will be tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility.

Barry J Byrne, MD, PhD, the chief medical advisor of MDA

MDA Care Centers and the Future of Gene Therapy in Neuromuscular Disease

Barry Byrne, MD, PhD;Noah Stansfield
February 2nd 2025
Article

Barry J Byrne, MD, PhD, the chief medical advisor of MDA, also shared his thoughts on the 75th anniversary of the organization.

FDA Activity Recap: January 2025 Features CRL, Multiple Clinical Holds, and More

FDA Activity Recap: January 2025 Features CRL, Multiple Clinical Holds, and More

CGTLive Staff
February 2nd 2025
Article

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

© 2025 MJH Life Sciences

All rights reserved.